Clinical Trials Now Recruiting in Ontario & Quebec
Clinical trials are being conducted by Concert Pharmaceuticals Inc., to investigate a new treatment called CTP‑543 in adults, age 18 to 65
The Promising Treatment CTP-543: Once or Twice Daily?
Concert Pharmaceutical's research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with
Concert Pharmaceuticals Reports on New Treatment for Alopecia Areata
Concert Pharmaceuticals is a leading company for the development of treatments similar to topical tofacitinib and topical ruxolitinib, both of which are